Kwanjoo Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kwanjoo Lee has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Dong Keon Yon
Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea
3 shared publications - Guillermo F. López Sánchez
Department of Public Health Sciences, Division of Preventive Medicine and Public Health, School of Medicine, University of Murcia, Murcia, Spain
2 shared publications - Jae Sung Ko
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Jong Woo Hahn
Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
2 shared publications Masoud Rahmati
Department of Physical Education and Sport Sciences Faculty of Literature and Human Sciences Lorestan University Khoramabad Iran
2 shared publicationsAbdullah Özgür Yeniova
Division of Gastroenterology Department of Internal Medicine Tokat Gaziosmanpaşa University Faculty of Medicine Tokat Turkey
1 shared publication
Latest Publications
- Open Access
- 15 September 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (5) , 709-710
Extracellular Vesicle Proteomics in Gastric Cancer: Moving Beyond Early Detection
Kwanjoo Lee, Jun-young Seo. Gut and Liver 2026;20:709-10. https://doi.org/10.5009/gnl260332
- 15 September 2026
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 20 (5) , 709-710
Open AccessExtracellular Vesicle Proteomics in Gastric Cancer: Moving Beyond Early Detection
Kwanjoo Lee, Jun-young Seo. Gut and Liver 2026;20:709-10. https://doi.org/10.5009/gnl260332
- Open Access
- 2 March 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (4) , 504-515
Global trends in incidence and prevalence of achalasia, 1925–2021: A systematic review and meta‐analysis
Background: Achalasia poses a significant socioeconomic burden, yet global trends remain undocumented. This study aims to describe the worldwide trends in the incidence and prevalence of achalasia from 1925 to 2021 and explore their correlation with various factors through a comprehensive systematic review.Methods: We searched the PubMed/MEDLINE, Embase, and Cochrane databases from inception to 30 June 2023, to identify studies reporting the incidence or prevalence of achalasia in the general population. This study utilized pooled estimates with 95% confidence intervals (CI) to estimate the incidence and prevalence of achalasia, and conducted various subgroup analyses.Results: A total of 26 eligible studies covering approximately 269 million participants and 20,873 patients from 14 countries across five continents were included. Global pooled incidence and prevalence of achalasia were estimated to be 0.78 cases per 100,000 person‐years (95% CI, 0.64–0.93; number of studies, 26; sample population, 269,315,171) and 10.82 cases per 100,000 person‐years (95% CI, 8.15–13.48; number of studies, 14; sample population, 192,176,076), respectively. The incidence of achalasia was higher in Oceania (than Asia and Africa) and in adults (than children) after the introduction of the Chicago classification. Prevalence followed a similar pattern. The pooled incidence of achalasia showed an overall upward trend from 1925 to 2021 (1925–1999; 0.40 [0.32–0.49] vs. 2018–2021; 1.64 [1.33–1.95] cases per 100,000 person‐years).Conclusions: The incidence and prevalence of achalasia have notably increased, particularly with advancements in diagnosis, and show significant variation worldwide, despite the large heterogeneity within the sample population. Further studies are necessary to accurately assess the global incidence and prevalence of achalasia.
- 2 March 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 12 (4) , 504-515
Open AccessGlobal trends in incidence and prevalence of achalasia, 1925–2021: A systematic review and meta‐analysis
Background: Achalasia poses a significant socioeconomic burden, yet global trends remain undocumented. This study aims to describe the worldwide trends in the incidence and prevalence of achalasia from 1925 to 2021 and explore their correlation with various factors through a comprehensive systematic review.Methods: We searched the PubMed/MEDLINE, Embase, and Cochrane databases from inception to 30 June 2023, to identify studies reporting the incidence or prevalence of achalasia in the general population. This study utilized pooled estimates with 95% confidence intervals (CI) to estimate the incidence and prevalence of achalasia, and conducted various subgroup analyses.Results: A total of 26 eligible studies covering approximately 269 million participants and 20,873 patients from 14 countries across five continents were included. Global pooled incidence and prevalence of achalasia were estimated to be 0.78 cases per 100,000 person‐years (95% CI, 0.64–0.93; number of studies, 26; sample population, 269,315,171) and 10.82 cases per 100,000 person‐years (95% CI, 8.15–13.48; number of studies, 14; sample population, 192,176,076), respectively. The incidence of achalasia was higher in Oceania (than Asia and Africa) and in adults (than children) after the introduction of the Chicago classification. Prevalence followed a similar pattern. The pooled incidence of achalasia showed an overall upward trend from 1925 to 2021 (1925–1999; 0.40 [0.32–0.49] vs. 2018–2021; 1.64 [1.33–1.95] cases per 100,000 person‐years).Conclusions: The incidence and prevalence of achalasia have notably increased, particularly with advancements in diagnosis, and show significant variation worldwide, despite the large heterogeneity within the sample population. Further studies are necessary to accurately assess the global incidence and prevalence of achalasia.
- Open Access
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (46) , e292
Global, Regional, and National Trends in Liver Disease-Related Mortality Across 112 Countries From 1990 to 2021, With Projections to 2050: Comprehensive Analysis of the WHO Mortality Database
Hahn JW, et al. J Korean Med Sci. 2024 Sep;39:e292. https://doi.org/10.3346/jkms.2024.39.e292
- 1 January 2024
- Published by XMLink in Journal of Korean Medical Science
- Vol. 39 (46) , e292
Open AccessGlobal, Regional, and National Trends in Liver Disease-Related Mortality Across 112 Countries From 1990 to 2021, With Projections to 2050: Comprehensive Analysis of the WHO Mortality Database
Hahn JW, et al. J Korean Med Sci. 2024 Sep;39:e292. https://doi.org/10.3346/jkms.2024.39.e292
- Top Cited PapersOpen Access
- 17 October 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 65, 102280
Global incidence and prevalence of autoimmune hepatitis, 1970–2022: a systematic review and meta-analysis
- 17 October 2023
- Published by Elsevier in eClinicalMedicine
- Vol. 65, 102280
Top Cited PapersOpen AccessGlobal incidence and prevalence of autoimmune hepatitis, 1970–2022: a systematic review and meta-analysis
- 23 April 2020
- Published by Georg Thieme Verlag KG
- Vol. 52 (S 01) , ePP103
USEFULNESS OF EUS-GUIDED FINE NEEDLE BIOPSY FOR SMALL PANCREATIC NEUROENDOCRINE NEOPLASM: KOREAN MULTICENTER NATIONWIDE STUDY
Aims Pancreatic neuroendocrine neoplasm (PNEN) represents heterogeneous biological behavior, and most of small PNENs 2 cm or less in size are known to show indolent feature. Thus, observation can be considered in selected cases according to the NCCN guideline, however, there is a lack of clinical evidence, and the criteria are vague. We evaluated the usefulness of EUS-guided fine needle biopsy in determination of treatment plan for small PNEN. Methods A total of 158 patients from 14 institutions with pathologically confirmed PNENs 2 cm or less in initial imaging were enrolled. The primary outcome was any event of metastasis or recurrence during follow up. Results The median age was 57.5 years (range, 22-84 years), and 86 patients (54%) were female. Eighteen patients (11%) had a tumor-related symptoms at initial diagnosis, and the median size of the tumor was 1.3 cm (range, 0.7-2.0 cm). The results of WHO classification were available in 147 patients: 126 patients (86%) with grade 1 and 21 patients (14%) with grade 2. Pathological diagnosis with EUS-guided aspiration biopsy was confirmed in 22 patients, and among them, identification of WHO classification was also available in 17 patients. Among six patients who underwent EUS-guided aspiration biopsy and surgery together, the concordance rate of WHO classification between two methods was 83% (5/6). A total of 142 patients (90%) underwent radical resection, and seven metastasis or recurrence (5%) were detected during follow up. WHO classification grade 2 was the only risk factor predicting metastasis or recurrence in univariate and multivariate analysis (HR 8.81, 95% CI 1.76-44.11, p = 0.008). Conclusions EUS-guided fine needle biopsy for small PNEN may be recommended to predict the malignant potential of the tumor by providing WHO classification.
- 23 April 2020
- Published by Georg Thieme Verlag KG
- Vol. 52 (S 01) , ePP103
USEFULNESS OF EUS-GUIDED FINE NEEDLE BIOPSY FOR SMALL PANCREATIC NEUROENDOCRINE NEOPLASM: KOREAN MULTICENTER NATIONWIDE STUDY
Aims Pancreatic neuroendocrine neoplasm (PNEN) represents heterogeneous biological behavior, and most of small PNENs 2 cm or less in size are known to show indolent feature. Thus, observation can be considered in selected cases according to the NCCN guideline, however, there is a lack of clinical evidence, and the criteria are vague. We evaluated the usefulness of EUS-guided fine needle biopsy in determination of treatment plan for small PNEN. Methods A total of 158 patients from 14 institutions with pathologically confirmed PNENs 2 cm or less in initial imaging were enrolled. The primary outcome was any event of metastasis or recurrence during follow up. Results The median age was 57.5 years (range, 22-84 years), and 86 patients (54%) were female. Eighteen patients (11%) had a tumor-related symptoms at initial diagnosis, and the median size of the tumor was 1.3 cm (range, 0.7-2.0 cm). The results of WHO classification were available in 147 patients: 126 patients (86%) with grade 1 and 21 patients (14%) with grade 2. Pathological diagnosis with EUS-guided aspiration biopsy was confirmed in 22 patients, and among them, identification of WHO classification was also available in 17 patients. Among six patients who underwent EUS-guided aspiration biopsy and surgery together, the concordance rate of WHO classification between two methods was 83% (5/6). A total of 142 patients (90%) underwent radical resection, and seven metastasis or recurrence (5%) were detected during follow up. WHO classification grade 2 was the only risk factor predicting metastasis or recurrence in univariate and multivariate analysis (HR 8.81, 95% CI 1.76-44.11, p = 0.008). Conclusions EUS-guided fine needle biopsy for small PNEN may be recommended to predict the malignant potential of the tumor by providing WHO classification.